• 7 results in Exploration of Targeted Anti-tumor Therapy
    Sort by
    Latest
    Open Access
    Original Article
    Understanding doxorubicin associated calcium remodeling during triple-negative breast cancer treatment: an in silico study
    Aim: Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer with high heterogeneity, rapid progression, and paucity of treatment options. The most effective chemotherape...
    Garhima Arora ... Samrat Chatterjee
    Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:208-226
    DOI: https://doi.org/10.37349/etat.2021.00042
    This article belongs to the special issue Calcium Signaling Apparatus in Cancers
    View:762
    Download:72
    Times Cited: 0
    Open Access
    Editorial
    Analysis of DNA from liquid biopsy: new genetic biomarkers for cancer immunotherapy?
    Carminia Maria Della Corte ... Floriana Morgillo
    Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:204-207
    DOI: https://doi.org/10.37349/etat.2021.00041
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:311
    Download:6
    Times Cited: 0
    Open Access
    Original Article
    Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitors
    Aim: Nuclear factor erythroid 2-related factor 2 (NRF2) is a key component in the cell’s response to oxidative and electrophilic stress and is a transcription factor regulating the expre...
    Ibrahim H. Kankia ... Yusuf Y. Deeni
    Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:187-203
    DOI: https://doi.org/10.37349/etat.2021.00040
    View:408
    Download:41
    Times Cited: 0
    Open Access
    Review
    Gastrointestinal disorders as immune-related adverse events
    Immune checkpoint inhibitors, such as cytotoxic T-lymphocyte antigen 4 inhibitors, programmed cell death 1 inhibitors and programmed cell death-ligand 1 inhibitors, have recently emerged as novel dr...
    Daniele Balducci ... Luca Maroni
    Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:174-186
    DOI: https://doi.org/10.37349/etat.2021.00039
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:350
    Download:9
    Times Cited: 0
    Open Access
    Review
    Liquid biopsy in NSCLC: a new challenge in radiation therapy
    Lung cancer is the most common cancer and the leading cause of cancer mortality worldwide. To date, tissue biopsy has been the gold standard for the diagnosis and the identification of specific mole...
    Annarita Perillo ... Ida Rosalia Scognamiglio
    Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:156-173
    DOI: https://doi.org/10.37349/etat.2021.00038
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:498
    Download:24
    Times Cited: 0
    Open Access
    Review
    Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
    About 15–20% of all breast cancers (BCs) are defined human epidermal growth factor receptor 2 (HER2)-positive, based on the overexpression of HER2 protein and/or amplification...
    Paolo Tarantino ... Giuseppe Curigliano
    Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:139-155
    DOI: https://doi.org/10.37349/etat.2021.00037
    View:1571
    Download:77
    Times Cited: 0
    Open Access
    Review
    Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review
    Fungal compounds have long been used for centuries as food supplements. β-glucans have been identified as the most interesting molecules with beneficial effects in several chronic diseas...
    Valeria Cognigni ... Rossana Berardi
    Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:122-138
    DOI: https://doi.org/10.37349/etat.2021.00036
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:708
    Download:34